Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | mFOLFOXIRI/PAN vs mFOLFOX6/PAN as initial treatment of patients with unresectable RAS & BRAF WT mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, provides an overview of the results of the Phase III TRIPLETE (NCT03231722) study which evaluated modified FOLFOXIRI plus panitumumab versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC). The intensification of the upfront chemotherapy backbone in combination with EGFR inhibition in molecularly selected and mostly left-sided mCRC did not provide any benefit in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.